Most important, however, is pre-exposure prophylaxis, or PrEP. For people at risk, PrEP can prevent HIV infection with extraordinary effectiveness, making it the single most powerful tool we have to ...

Add Yahoo as a preferred source to see more of our stories on Google. Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or ...

The landscape of HIV prevention has undergone a profound transformation with significant advancements in medical interventions and a deeper understanding of how the virus spreads. These developments ...

A Lancet study found long-acting injectable cabotegravir provided greater protection against HIV than daily oral PrEP, ...

Global efforts to prevent HIV lost ground last year as funding disruptions forced countries to scale back services, even as ...

Human immunodeficiency virus-1 (HIV-1) remains a global health crisis, with over 40 million people living with the virus and no effective vaccine available. Central to HIV infection and immune evasion ...

HIV (human immunodeficiency virus) remains a significant global health challenge, affecting millions of people worldwide. While advancements in medical science have led to better management of the ...

Featured individuals were compensated for their time. Sex should feel good, pleasurable, and uninhibited. But protecting your sexual health is still an important part of the experience. HIV prevention ...

Share on Pinterest Lenacapavir is a twice-yearly injection to prevent HIV that could improve adherence rates compared to other PrEP medications. d3sign/Getty Images The WHO issued a global ...

After sessions with Gilead's leadership at Morgan Stanley's 2026 Global Healthcare Conference, the bank reaffirmed its ...

A recent University of Mississippi study has identified hundreds of counties in the South where HIV prevention and health care may not be keeping pace with the local needs, leaving communities without ...

The collaboration enables 14 countries to access lenacapavir for PrEP outside of Gilead’s current voluntary licensing ...